Erector Spinae Plane Block in Congenital Heart Disease Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age32-18
SponsorStanford University

About this trial

Pediatric cardiac patients undergoing surgical anesthesia are at an increased risk of poor neurologic outcome (20-50%). Unattenuated anesthetic exposure and pain contributes to physiologic perturbations that may increase neurologic morbidity. Because of the often-large exposure to anesthetic agents in these cardiac children, at such a young age and the potential modifying anesthetic practice that could lead to improved neurodevelopmental outcomes and surgical recovery is paramount. Regional anesthesia such as thoracic epidurals provide effective analgesia and reduced intraoperative anesthetic needed but carry devastating sequelae neurological risks of epidural hematomas after anticoagulation during cardiopulmonary bypass (CPB). Recently, a newly described erector spinae plane block (ESPB) is superficial to neuraxial or vascular structures, providing opportunity to be placed with less risk for surgery requiring CPB. This block has been described as effective regional anesthesia for adult cardiac surgery.

Eligibility criteria

Qualifiers

Neonates of at least 32 weeks of gestation, infants and children admitted to The Lucile Packard Children's Hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention.

Admitting diagnosis of cyanotic or non-cyanotic heart disease

Disqualifiers

Neonates less than 32 weeks of gestational age

Any documented central nervous system malformations.

Any potential subject requiring unexpected postoperative Extracorporeal membrane oxygenation (ECMO) support

Trial design

Treatments tested in this trial

  • Erector Spinae Plane Block

Treatment groups

150 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators